FIT Biotech Oy: Correction to English company release: Conversion of FIT Biotech Oy’s Convertible Notes into shares – FIT Biotech

Reports and Releases

FIT Biotech Oy: Correction to English company release: Conversion of FIT Biotech Oy’s Convertible Notes into shares

FIT Biotech Oy

Company release October 14, 2016 at 1 pm EET

Correction to English company release: Conversion of FIT Biotech Oy's Convertible Notes into shares

FIT Biotech Oy's company release published on October 14, 2016 at 9.30 am EET contained an error related to the amount of new K shares issued by the Company to Bracknor due to the conversion of Convertible Notes. The correct number of new K shares is 124,890 as stated in the Finnish company release.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media

Back to list